ArticleJournal of advanced research2026
Bacteroides vulgatus alleviates heart failure via butyric acid-TGF-β1/MAPK pathway.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microbiota metabolite butyrate alleviates intestinal inflammation associated with enhanced autophagy-related signaling in DSS-induced colitis.Frontiers in immunology · 2026Article
- The gut microbiota: an emerging therapeutic target for ICI-associated myocarditis.Frontiers in cellular and infection microbiology · 2026Review
- The gut-heart axis in heart failure: from bidirectional pathophysiological mechanisms to integrative therapeutic strategies.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe gut microbiota plays a vital role in the progression of heart failure (HF), making it a potential strategy for treating HF. The Bacteroides genus has shown promising potential for treating HF. However, further research is needed to identify specific beneficial Bacteroides strains for treating HF and elucidate their potential mechanisms.
objectivesThis study aimed to elucidate the therapeutic effect and mechanism of Bacteroides strain on HF.
methodsThis study comprehensively used pharmacological evaluation, 16S rRNA genetic sequencing, short-chain fatty acid (SCFA) targeted metabolomics, transcriptome, and molecular biology methods to investigate the efficacy and mechanism of Bacteroides vulgatus (B. vulgatus) in the treatment of HF.
resultsWe observed a significant decrease in the abundance of B. vulgatus in both HF patients and mice, and dysbiosis of the gut microbiota could cause cardiac dysfunction in mice. The administration of B. vulgatus to mice with HF significantly improved their cardiac function and significantly increased the levels of SCFAs, especially butyric acid. Meanwhile, we also observed a significant reduction in the level of butyric acid in the serum of HF patients, and the cardiac function of HF mice improved after the administration of butyric acid. Compared to patients with higher butyric acid level, patients with lower butyric acid level had a significantly increased incidence of endpoint events. Moreover, the transcriptome results revealed that B. vulgatus significantly regulated the mitogen-activated protein kinase (MAPK) pathway. After further molecular biology verification, B. vulgatus was confirmed to regulate the transforming growth factor-β1 (TGF-β1)/MAPK pathway in the heart through butyric acid, thereby exerting anti-HF effects.
conclusionThis study provides evidence that B. vulgatus improves heart function by regulating SCFA metabolism and subsequently modulating the TGF-β1/MAPK pathway in myocardial tissue, confirming the potential therapeutic role of B. vulgatus in HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.